If you are receiving your cancer treatment at an infusion space in North Carolina Basnight Cancer Hospital (NCBCH), you may be able to take part in a research study. This study aims to understand your satisfaction and experience in the infusion spaces during your treatment.

This study will check muscle mass, physical function, and cancer-related aging in children and young adults (8-21 years old) undergoing cancer treatment. In this study, we want to learn how muscle and physical function (strength, mobility, endurance) change in children and young adults who undergoing cancer treatment and how to measure these changes.

This purpose of this study is to learn the best way to build advocacy skills for parents/caregivers of transition age youth with IDD. The goal is to improve parent and youth health and emotional well-being. Parents will attend a group with other parents; the groups will meet 4 times, once a week for 1 hour. The research team will collect 4 surveys from parents, 4 brief surveys from youth if the parent feels they are able to provide information, 4 audio-recordings of parent-provider conversations, and video-recordings of group sessions. Parents and youth will be compensated for their time.

The purpose of this study is to determine the extent to which various forms of language exposure affect a second-language Spanish speaker's production of a specific dialectal feature

Do you have asymptomatic multiple myeloma, also known as smoldering multiple myeloma? You may be able to take part in a research study to help us learn more about the effectiveness of a drug called daratumumab in combination with lenalidomide and steroids.

Have you been diagnosed with high-risk non-muscle invasive bladder cancer which has not responded to initial treatment with Bacillus Calmette-Guerin (BCG)? If so, you may be able to take part in a research study evaluating the safety of adding the study drug called pembrolizumab to an existing treatment option for bladder cancer patients.

Have you been diagnosed with oropharyngeal (tonsil or tongue base) cancer. If so, you may be able to take part in a research study testing markers to determine who may be appropriate for less aggressive therapy and markers to determine if recurrent tumors can be detected earlier.

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.

Do you have relapsed or refractory multiple myeloma? Have you received at least one type of treatment? If so, you may be able to take part in a research study looking at the the safety of giving an investigational medication to patients with multiple myeloma.

Do you currently have a cancerous tumor that has advanced or progressed? Are you currently not on any standard of care treatment options? If so, you may be able to take part in a research study to see if a new drug may be able to slow the growth of your cancer. Travel reimbursement and compensation provided.